Eiger BioPharmaceuticals Inc. (EIGR) Shares Up 2.8%
Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) shot up 2.8% during trading on Monday . The company traded as high as $20.00 and last traded at $20.00, with a volume of 55,665 shares changing hands. The stock had previously closed at $19.45.
A number of brokerages have commented on EIGR. Zacks Investment Research downgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 7th. Wedbush reissued a “buy” rating and issued a $36.00 price objective on shares of Eiger BioPharmaceuticals in a research report on Monday, June 13th. Piper Jaffray Cos. reissued a “buy” rating and issued a $33.00 price objective (up from $30.00) on shares of Eiger BioPharmaceuticals in a research report on Thursday, April 21st. Jefferies Group reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a research report on Thursday, April 14th. Finally, Oppenheimer Holdings Inc. began coverage on shares of Eiger BioPharmaceuticals in a research report on Tuesday, July 5th. They issued an “outperform” rating and a $34.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Eiger BioPharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $34.50.
The company’s 50-day moving average price is $19.53 and its 200-day moving average price is $18.48. The company’s market cap is $142.09 million.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its earnings results on Monday, May 16th. The company reported ($10.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.69) by $8.73. On average, analysts predict that Eiger BioPharmaceuticals Inc. will post ($7.88) earnings per share for the current fiscal year.
In related news, CFO James H. Welch bought 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were acquired at an average cost of $19.80 per share, with a total value of $49,500.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares of the company’s stock, valued at $39,600. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James P. Shaffer bought 1,250 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The stock was bought at an average cost of $22.17 per share, for a total transaction of $27,712.50. Following the completion of the transaction, the insider now directly owns 1,975 shares of the company’s stock, valued at approximately $43,785.75. The disclosure for this purchase can be found here.
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.